Rhythm Pharmaceuticals Inc (RYTM) — Cash Flow-to-Debt Ratio
Rhythm Pharmaceuticals Inc (RYTM) has a Cash Flow-to-Debt Ratio of -0.07x as of December 2025, meaning its operating cash flow of $-25.39 Million could theoretically repay 0% of its total liabilities ($342.12 Million) in one year. Explore RYTM long-term investments to assets to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Rhythm Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Rhythm Pharmaceuticals Inc across 14 annual periods. Also explore RYTM total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Rhythm Pharmaceuticals Inc (2012–2025)
Year-by-year debt coverage analysis for Rhythm Pharmaceuticals Inc. For market capitalisation and broader financial context, see market cap of Rhythm Pharmaceuticals Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.34x | $-115.67 Million | $342.12 Million | ▲ +32.4% |
| 2024 | -0.50x | $-113.88 Million | $227.72 Million | ▲ +40.1% |
| 2023 | -0.84x | $-136.16 Million | $162.99 Million | ▲ +43.1% |
| 2022 | -1.47x | $-173.43 Million | $118.22 Million | ▲ +54.4% |
| 2021 | -3.22x | $-146.00 Million | $45.37 Million | ▲ +45.8% |
| 2020 | -5.94x | $-121.98 Million | $20.55 Million | ▼ -33.0% |
| 2019 | -4.46x | $-122.75 Million | $27.50 Million | ▼ -0.4% |
| 2018 | -4.45x | $-62.06 Million | $13.95 Million | ▼ -4.9% |
| 2017 | -4.24x | $-29.46 Million | $6.95 Million | ▲ +7.9% |
| 2016 | -4.61x | $-23.22 Million | $5.04 Million | ▼ -248.1% |
| 2015 | -1.32x | $-6.98 Million | $5.27 Million | ▲ +90.3% |
| 2014 | -13.60x | $-7.51 Million | $552.00K | ▼ -5271.1% |
| 2013 | -0.25x | $-19.16 Million | $75.65 Million | ▲ +21.6% |
| 2012 | -0.32x | $-17.83 Million | $55.21 Million | — |